AU2016338916B2 - Enhancing beta cell replication and/or survival - Google Patents

Enhancing beta cell replication and/or survival Download PDF

Info

Publication number
AU2016338916B2
AU2016338916B2 AU2016338916A AU2016338916A AU2016338916B2 AU 2016338916 B2 AU2016338916 B2 AU 2016338916B2 AU 2016338916 A AU2016338916 A AU 2016338916A AU 2016338916 A AU2016338916 A AU 2016338916A AU 2016338916 B2 AU2016338916 B2 AU 2016338916B2
Authority
AU
Australia
Prior art keywords
gaba
pam
activating ligand
receptor activating
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016338916A
Other languages
English (en)
Other versions
AU2016338916A1 (en
Inventor
Daniel L. Kaufman
Jide Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Publication of AU2016338916A1 publication Critical patent/AU2016338916A1/en
Application granted granted Critical
Publication of AU2016338916B2 publication Critical patent/AU2016338916B2/en
Priority to AU2022202004A priority Critical patent/AU2022202004B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016338916A 2015-10-14 2016-10-12 Enhancing beta cell replication and/or survival Active AU2016338916B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022202004A AU2022202004B2 (en) 2015-10-14 2022-03-23 Enhancing beta cell replication and/or survival

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562241566P 2015-10-14 2015-10-14
US62/241,566 2015-10-14
US201662279908P 2016-01-18 2016-01-18
US62/279,908 2016-01-18
PCT/US2016/056528 WO2017066240A1 (en) 2015-10-14 2016-10-12 Enhancing beta cell replication and/or survival

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022202004A Division AU2022202004B2 (en) 2015-10-14 2022-03-23 Enhancing beta cell replication and/or survival

Publications (2)

Publication Number Publication Date
AU2016338916A1 AU2016338916A1 (en) 2018-05-31
AU2016338916B2 true AU2016338916B2 (en) 2021-12-23

Family

ID=58518528

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016338916A Active AU2016338916B2 (en) 2015-10-14 2016-10-12 Enhancing beta cell replication and/or survival
AU2022202004A Active AU2022202004B2 (en) 2015-10-14 2022-03-23 Enhancing beta cell replication and/or survival

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022202004A Active AU2022202004B2 (en) 2015-10-14 2022-03-23 Enhancing beta cell replication and/or survival

Country Status (7)

Country Link
US (1) US20180235916A1 (enExample)
EP (1) EP3362069A4 (enExample)
JP (2) JP6957455B2 (enExample)
KR (1) KR20180054796A (enExample)
CN (1) CN108697712A (enExample)
AU (2) AU2016338916B2 (enExample)
WO (1) WO2017066240A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
EP3642206A4 (en) * 2017-06-23 2021-04-07 The Regents of The University of California INCREASED GABA ABILITY TO MODULATE IMMUNE REACTIONS
WO2020081886A1 (en) * 2018-10-18 2020-04-23 The Regents Of The University Of California Homotaurine for treatment of inflammation-related disorders
JP2023509981A (ja) * 2020-01-10 2023-03-10 エキリーブル バイオファーマシューティカルズ べスローテン フェンノートシャップ アベルメクチンによる神経障害の治療
US20250375429A1 (en) * 2024-05-29 2025-12-11 Smarter Not Harder, Inc. Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2014048788A1 (en) * 2012-09-27 2014-04-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for producing a population of pancreatic beta-cells
WO2015140081A1 (en) * 2014-03-18 2015-09-24 Algiax Pharmaceuticals Gmbh 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050034A1 (en) * 1999-02-24 2000-08-31 The Regents Of The University Of California Gaba receptors mediate inhibition of t cell responses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2014048788A1 (en) * 2012-09-27 2014-04-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for producing a population of pancreatic beta-cells
WO2015140081A1 (en) * 2014-03-18 2015-09-24 Algiax Pharmaceuticals Gmbh 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHWEH A Y ET AL, "Effect of GABA agonists on the neurotoxicity and anticonvulsant activity of benzodiazepines", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 36, no. 8, (1985-02-25), pages 737 - 744, (1985-02-25) *
DAVIES L P ET AL, "Substituted imidazo[1,2-b]pyridazines", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 44, no. 8, ISSN 0006-2952, (1992-10-20), pages 1555 - 1561, (1992-10-20) *
E S El-Denshary ET AL, "Effects of tetracycline and diazepam on insulin secretion and adenylyl cyclase activity of isolated rat islets of Langerhans.", Diabete Metab. 1977 Mar;3(1):3-6., (1977-01-01), pages 3 - 6, *
J. TIAN ET AL, "-Aminobutyric Acid Regulates Both the Survival and Replication of Human -Cells", DIABETES, US, (2013-08-30), vol. 62, no. 11, doi:10.2337/db13-0931, ISSN 0012-1797, pages 3760 - 3765 *
JIDE TIAN ET AL, "Clinically applicable GABA receptor positive allosteric modulators promote ß-cell replication", SCIENTIFIC REPORTS, (2017-03-23), vol. 7, no. 1, doi:10.1038/s41598-017-00515-y *
PAUL SM, "Alcohol-sensitive GABA receptors and alcohol antagonists", 2006-05-22, (2006-05-22) *
RAMIREZ G ET AL, "Gabaergic modulation of acetylcholine release in cholinergic synaptosomes from Torpedo marmorata electric organ", NEUROSCIENCE, NEW YORK, NY, US, vol. 30, no. 1, (1989-01-01), pages 251 - 255. *
Riitta Selkgmaa ET AL, "Photochemical decomposition of midazolam. I. Isolation and identification of products", Inrernotional Journal of Pharmaceutics, (1989-01-01), pages 83 - 89. *
Surwit et al. Psychosomatic Medicine, vol. 48, No. 3/4, March/April, 1986. (Year: 1986) *

Also Published As

Publication number Publication date
AU2022202004B2 (en) 2024-09-19
KR20180054796A (ko) 2018-05-24
JP6957455B2 (ja) 2021-11-02
WO2017066240A1 (en) 2017-04-20
AU2022202004A1 (en) 2022-04-14
EP3362069A4 (en) 2019-10-02
EP3362069A1 (en) 2018-08-22
US20180235916A1 (en) 2018-08-23
CN108697712A (zh) 2018-10-23
AU2016338916A1 (en) 2018-05-31
JP2018530581A (ja) 2018-10-18
JP2022008902A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
AU2022202004B2 (en) Enhancing beta cell replication and/or survival
KR101546031B1 (ko) Ｃｍｔ 및 관련 장애를 치료하기 위한 신규 치료적 접근법
Cutrer et al. Possible mechanisms of valproate in migraine prophylaxis
EP2892518B1 (en) Compositions for treating parkinson's disease
AU2009259336B2 (en) Combination of pilocarpin and methimazol for treating Charcot-Marietooth disease and related disorders
US11992495B2 (en) Enhancing GABA's ability to modulate immune responses
GB2448224A (en) Combination of a nicotine receptor agonist and a dopaminergic agent with reduced side effects in the treatment of Parkinson's disease and the like
US20130045988A1 (en) Combination therapy
Rezvani et al. Sub-anesthetic doses of ketamine attenuate nicotine self-administration in rats
US20080085920A1 (en) Compositions Comprising Nb-Dnj, Ne-Dnj Or D-Glucaro-Delta-Lactam And Their Uses For The Treatment Of Pain And Other Neurological Condittions
Liu et al. Neuroprotective effect of pseudoginsenoside-F11 on permanent cerebral ischemia in rats by regulating calpain activity and NR2A submit-mediated AKT-CREB signaling pathways
EP1673107B1 (en) Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
US10533012B2 (en) (R)-pirlindole and its pharmaceutically acceptable salts for use in medicine
CA3043292C (en) Enhancing beta cell replication and/or survival
CA3043292A1 (en) Enhancing beta cell replication and/or survival
HK1262672A1 (en) Enhancing beta cell replication and/or survival
US20060199866A1 (en) Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse
Liu Identification and Characterization of Antidiabetic and Antihypertensive Agents from Three Traditional Herbal Medicines
WO2025096942A1 (en) Trimeprazine for use in treating pain associated with trigeminal neuralgia
IL324407A (en) Btk inhibitor for treating multiple sclerosis
Elhauge et al. (425) Dissolution studies in the presence of alcohol with an abuse-deterrent, extended-release morphine product candidate
AU2018273482A1 (en) Novel multitarget drug for treating diseases in mammals

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)